Group 1 - The core viewpoint of the article highlights that Baiaosaitu-B (02315) experienced a significant stock price increase, reaching a new high of 39.46 HKD, with a current increase of 7.86% at 38.72 HKD and a trading volume of 17.64 million HKD [1] - On January 9, Baiaosaitu announced a licensing agreement with Yushibo to systematically evaluate the BsADC projects, aiming to accelerate the development of BsAD2C [1] - The agreement grants Yushibo an option for exclusive global licensing of two BsADC projects from Baiaosaitu, which will receive an upfront payment and subsequent payments upon the exercise of the option, including milestone payments and revenue sharing [1] Group 2 - According to recent research from Cinda Securities, Baiaosaitu's business model, which includes sales of model animals and preclinical pharmacological evaluations, is experiencing rapid growth [1] - Compared to peers, Baiaosaitu's business model is unique, focusing on high-margin humanized mouse strains and avoiding low-margin standard strains, leading to high utilization of cage resources and international expansion capabilities [1]
港股异动 | 百奥赛图-B(02315)盘中涨近10% 股价刷新上市新高 与育世博达成进一步合作